key: cord-0982867-em936a7z
authors: Zhang, Yali; Wei, Min; Wu, Yangtao; Wang, Juan; Hong, Yuting; Huang, Yang; Yuan, Lunzhi; Ma, Jian; Wang, Kai; Wang, Shaojuan; Shi, Yang; Wang, Zikang; Guo, Huilin; Xiao, Jin; Yang, Chuanlai; Ye, Jianghui; Chen, Jijing; Liu, Yuxi; Fu, Baorong; Lan, Miaolin; Gong, Peixuan; Huang, Zehong; Su, Yingying; Chen, Yixin; Zhang, Tianying; Zhang, Jun; Zhu, Huachen; Yu, Hai; Yuan, Quan; Cheng, Tong; Guan, Yi; Xia, Ningshao
title: Cross-species tropism and antigenic landscapes of circulating SARS-CoV-2 variants
date: 2022-03-07
journal: Cell Rep
DOI: 10.1016/j.celrep.2022.110558
sha: 9e11d95e5405b050dd5cf1f730376dc11a7c6fb7
doc_id: 982867
cord_uid: em936a7z

Mutations in the SARS-CoV-2 spike receptor-binding domain (RBD) may alter viral host tropism and affect the activities of neutralizing antibodies. Here, we investigated 153 RBD mutants and 11 globally circulating VOC/VOI variants (including Omicron) for their antigenic changes and cross-species tropism in cells expressing 18 ACE2 orthologs. Several RBD mutations strengthened viral infectivity in cells expressing ACE2 orthologs of non-human animals, particularly those less susceptible to the ancestral strain. The mutations surrounding aa 439-448 and aa 484 are more likely to cause neutralization resistance. Strikingly, enhanced cross-species infection potential in the mouse and ferret, instead of the neutralization-escape scores of the mutations, account for the positive correlation with the cumulative prevalence of mutations in humans. These findings present insights for potential drivers of circulating SARS-CoV-2 variants and provide informative parameters for tracking and forecasting spreading mutations.

The emerging variants of the pandemic SARS-CoV-2 bring enormous challenges to 2 public health (Lauring and Hodcroft, 2021) . Mutations occurring in viral spike protein, 3 particularly in the receptor-binding domain (RBD), may change the protein conformation 4 and affect the interaction with the host ACE2 receptor. In addition, some RBD mutations 5 may cause the cross-species spillover by introducing the ACE2-binding capacity to non-6 human species that SARS-CoV-2 were initially insusceptible. Moreover, because the RBD 7 is the primary target of the neutralizing antibody (nAb) response elicited by natural infection 8 or vaccine immunization, RBD mutations may confer nAb resistance and possibly increase 9 the re-infection risk reducing the effectiveness of vaccines based on the original virus. 10 Given the widespread and continuous evolution of SARS-CoV-2, multiple variants 11 constantly emerged. So far, five variants of concern (VOC) have been designated: the Omicron; and the T478K in the Delta and Omicron. Before Omicron's emergence, the 18 K417N/E484K/N501Y harbored Beta variant showed the most noticeable resistance to 19 nAbs acquired from natural infection or vaccine immunization (Garcia-Beltran et al., 2021; 20 Wang et al., 2021; Zhou et al., 2021) . The Omicron (B.1.1.529), a recently documented 21 and highly contagious VOC harboring ~15 RBD mutations, is spreading rapidly worldwide 22 and has become a severe threat as its more aggressive immune evasion ability 23 (Dejnirattisai et al., 2022; Hoffmann et al., 2021) . Several studies have investigated the 24 antigenic influence of representative RBD mutations. However, the fully antigenic 25 landscapes of RBD mutants and their cross-species tropism remain to be explored. 26 Exploring the underlying association between the biological impacts and the circulating 27 prevalence of RBD mutations will be informative for forecasting the variants which may be 28 prevalent in the future. 29 Based on the analyses of viral sequences deposited at the public SARS-CoV-2 30 J o u r n a l P r e -p r o o f 4 / 30 genome database, we generated a panel of lentiviral-pseudotyped particles (LVpp) 1 composed of 129 single-site RBD mutants, 24 double-site RBD (DM) mutants, and 11 2 VOC/VOIs variants, including the newly emerged Omicron. The infection potentials of 3 these variants in cells expressing various ACE2 from 18 animal species were evaluated. 4 In addition, the neutralizing resistance of variants to human convalescent plasmas (HCPs), 5 vaccine or vaccine candidates derived polyclonal and monoclonal antibodies (mAbs) were 6 also investigated. More importantly, the association among the cumulative frequencies of 7 circulating RBD mutations and their cross-species infection potentials and neutralization 8 escape characteristics were systematically analyzed. 9

Impact of RBD mutations on the function of spike 11 We initially tracked the RBD mutations since Aug 2020. Based on the analyses of viral 12 spike gene variation annotations from the 2019nCoVR database of CNCB, a total of 129 13 RBD mutations were selected for further tests. The spatial locations and frequencies of 14 these mutations in the spike/ACE2 complex structure are illustrated in Figure 1A . For LVpp 15 productions, we generated the spike-expressing plasmids with single-site mutations in 16 combination with D614G. The 18aa of spike C-terminus was replaced with a HiBit 17 bioluminescent tag for antibody-free detection ( Figure S1A ). Compared to the parental 18 D614G (designated S-614G), we noted 17 mutants (13.2%) showed >50% spike-19 expressing reduction, and 7 (5.4%) had notably decreased spike secretions ( Figure S1B ). 20 In huACE2-H1299 cells, 17 RBD mutants showed >5-fold decreased infectivity to S-614G Broad tropism of SARS-CoV-2 for both terrestrial and marine mammals 27 A total of 18 ACE2 orthologs from various species were selected to set a panel for 28 assessment in mediating cellular entry of SARS-CoV-2 variants (Table S1 ). The key 29 variation residues in these orthologs at the RBD/ACE2 binding interface are shown in 30 J o u r n a l P r e -p r o o f 5 / 30 Figure 1C . The H1299, a human lung tumor-derived cell with deficient endogenous ACE2 1 but is TMPRSS2-expressing, was used to develop ACE2-reconstituted cells (Ou et al., 2 2021; Zhang et al., 2021) . Exogenous reconstitution of human ACE2 could efficiently 3 render the H1299 cells susceptible to SARS-CoV-2 LVpp (Zhang et al., 2021) . Therefore, 4 we generated 18 stable H1299 cell lines with exogenous expression of various ACE2 5 orthologs. Flow cytometry (FACS) analyses demonstrated all cell lines had a >99% positive 6 rate for integrated mRuby3 expression ( Figure S2 ). The fluorescent spike probe CoV2-STG) (Zhang et al., 2021) showed efficient bindings with 13 of 18 cells, except those 8 transfected with ACE2 of the ferret, horseshoe bat, mouse, brown trout, and tupaia, in 9 either FACS ( Figure S2 ) or imaging assays ( Figure S3 ). Recombinant ACE2-Fc chimeric 10 proteins (rACE2) of these orthologs were produced for biochemical analyses ( Figure S4 ). 11 The ELISA-binding capabilities of the rACE2 proteins to two recombinant SARS-CoV-2 S-12 ectodomain proteins HexaPro) (Hsieh et al., 2020; Wu et al., 2021) are shown in Figure S5A . The rACE2 proteins 14 of human, rhesus macaque, hamster, rabbit, cat, pig, puma, pangolin, and dog showed an 15 EC50<100 ng/mL for both S proteins suggesting potent ACE2-Spike bindings ( Figure 1D , 16 left panel). The LVpp infection assays demonstrated that most cell lines could efficiently 17 support the ancestral virus entry ( Figure 1D , right panel), except those with ACE2 of tupaia, 18 horseshoe bat, ferret, mouse, and brown trout ( Figure S5B ). The ACE2 of two marine 19 mammals, sea lion, and whale, also efficiently rendered cells susceptible to 20 despite only having moderate-to-low binding to S proteins. Overall, the binding capabilities 21 of rACE2 proteins to S-ectodomain proteins positively correlate with the apparent viral 22 infectivity in H1299 cells expressing the corresponding ACE2 ( Figure 1D ). An EC50<3.5 23 log10 ng/mL determined by rACE2-spike binding ELISA is likely to be a crucial requirement 24 for efficient SARS-CoV-2 pseudovirus infection. 25 26 To determine host tropism influence of RBD mutations, we evaluated the 27 susceptibilities of 18 ACE2-expressing H1299 cells to 112 RBD mutants (17 infectivity-28 decreased variants were excluded). In cells expressing ACE2 orthologs that can support 29 efficient infection of the ancestral virus, most of the mutants preserved comparable 30 J o u r n a l P r e -p r o o f 6 / 30 infectivity to S-614G (<2-fold changes, Figures 2A and S5C ). Of note, the susceptibility of 1 H1299 cells with ferret ACE2 (feACE2) was quite sensitive to RBD mutations (Figure 2A).   2   The P330S, N439K, L452R, Y453F, E484K/Q, Q493L, and N501Y exhibited a ~2-fold   3 increased infection performance to S-614G in feACE2 cells (Figure 2A ). In cells expressing 4 mouse ACE2 (muACE2), the K417N, E484K, and N501Y conferred dramatically increased 5 infectivity ( Figure 2A) showed ≥3× infection improvements in the whale ACE2-expressing cells (Figure 2A and 10 S5C). By contrast, in cells with ACE2 of tupaia (tuACE2) or brown trout (btACE2), no 11 mutation showed a markedly promoting effect for viral infection ( Figure 2A ). 12 We next assessed 11 VOC/VOI variants ( Figure 2B and 2C), including the newly 13 documented Omicron, for their infectivities in cells expressing ACE2 orthologs of human, 14 mouse, ferret, horseshoe bat, and tupaia. In huACE2 cells, the Alpha, Beta, Gamma, 15 Epsilon, Eta, Iota, Delta, and Omicron variants, as well as the N501Y/E484K and 16 N501Y/K417N DM mutants, showed 1.3-3.7×increase (p<0.001) in infectivity than S-614G 17 ( Figure 2B ). In contrast, the LVpp of Eta and B.1.620 displayed reduced infectivity (p<0.001) 18 ( Figure 2B ). In agreement with the single-site RBD mutant tests, variants harboring the 19 N501Y, particularly for the Alpha, Beta, Gamma, Omicron, and two DM mutants, exhibited 20 a dramatically and hundred-folds increased infectivity in muACE2 cells (p<0.001, Figure   21 2B). The Eta, Iota_E484K, and B.1.620, carrying E484K but not N501Y, displayed 22 approximately 10-30× increased infectivity in muACE2 cells. These findings suggested that 23 the N501Y played the most conspicuous contribution in rendering muACE2 cells 24 susceptible to SARS-CoV-2. Moreover, the E484K also had an enhanced effect on the viral 25 infectivity in muACE2 cells, even though it was less efficient than the N501Y. Interestingly, 26 the Kappa (with L452R/E484Q) and Delta (with L452R/T478K) variants also showed 27 significantly increased infectivity in muACE2 cells ( Figure 2B ). However, neither L452R, 28 T478K nor E484Q exhibited such effect in the single-site mutant tests ( Figure 2A ). 29 Therefore, it was possibly attributed to a potential synergistic effect of the dual-mutations 30 J o u r n a l P r e -p r o o f 7 / 30 of L452R/E484Q or L452R/T478K. Moreover, the feACE2 cells showed significantly 1 increased (2.4-22× increase to S-614G, and p<0.001 for each comparison) susceptibilities 2 to 11 tested VOC/VOI variants and the N501Y/E484K mutant but was less susceptible to 3 the N501Y/K417N ( Figure 2B and 2C). In hbACE2 cells ( Figure 2C ), the infectivity of Beta, 4 Gamma, Eta, Iota_E484K, Kappa, Delta, B.1.620, Omicron, and N501Y/E484K were 5 slightly increased (2.2-13× increase to S-614G, p<0.001). In contrast, no significant 6 infectivity change was observed for the Alpha, Epsilon, Iota_S477N, and N501Y/K417N 7 (p>0.05). Notably, in the hbACE-H1299 cells, enhanced infectivity of the Omicron variant 8 may be attributed to the N440K (Figure 2A ). As a control, untransfected H1299 cells only 9 showed weak infection signals even at the highest virus dose tested ( Figure 2B ). 10 Compared to the control cells, none of the tested variants presented improved infectivity in 11 tuACE2 or btACE2 cells ( Figure S5D ). 12 Overall, these results suggest that several circulating RBD mutants have enhanced 13 infectivity in cells that expressed ACE2 orthologs of non-human animals, particularly for 14 the mouse and ferret. The increased infection potentials of RBD mutants in animals may 15 expand the host range of SARS-CoV-2 and possibly cause cross-species spillover.

To investigate the mutations-related influence to antibodies induced by ancestral spike 18 derivates, we first tested the neutralizing activities of 9 mAbs against 48 mutants with 19 mutations in the receptor-binding motif (RBM) ( Figure 3A ). Among these mAbs, the 4A8 is 20 an NTD-targeting nAb, and others are RBD-targeting nAbs. The 4A8, COVA2-15, BD368-21 2, and S2M11 were reported human mAbs isolated patients who've recovered from 22 COVID-19 (Brouwer et al., 2020; Cao et al., 2020; Chi et al., 2020; Tortorici et al., 2020) ; 23 the REGN10933 was isolated from humanized mice (Hansen et al., 2020) ; the 3C8, 36H6, 24 2B4, and 85F7 were mouse mAbs developed in our lab (Wu et al., 2022; Zhang et al., 25 2021) . According to the recognizing modes of these mAbs, the REGN10933 and 3C8 are 26 Class 1 nAbs; BD368-2, COVA2-15, and 36H6 are Class 2 nAbs; 85F7 and S2M11 are 27 Class 3 nAbs; 2B4 is a Class 4 nAb ( Figure 3A ) (Barnes et al., 2020; Wu et al., 2022) . The 28 potencies of these mAbs were quantified as IC50 values in neutralizing assay ( Figure S6 ). 29 An >4× relative neutralizing potency (rNP) decrease (>4× IC50 increase to that against S-30 J o u r n a l P r e -p r o o f 8 / 30 614G) was considered a marked immune escape. As the 4A8 is an NTD-targeting mAb, 1 little change was observed in its activity against tested mutants ( Figure S6A) (Chang et al., 2021; Zhang et al., 2021) . Their cross-neutralization activities against 27 mutants were determined as the relative neutralizing titers (rNT) to control (the NT ratio of 28 against mutant to that against S-614G). Among all mutants, the neutralizing potency of 29 human rACE2 (rhuACE2) showed an >2-fold increase against the N501Y and T478K/R, suggesting that the three mutants may have a higher binding capability huACE2 ( Figure   1 3B). We focused on the mutations leading to >50% neutralization decrease of the HCPs, 2 as shown in Figure 3B . Overall, the P018 and P019 exhibited a similar cross-neutralization 3 pattern (R 2 =0.52, p<0.001) to most variants, but the P020 had a different antigenic profile 4 ( Figure S7A ). Mutations surrounding aa 439-448, such as N439K, N440K, K444N/R, 5 G446V, and N448D/H/Y, caused more marked neutralization reduction on P018 and P019 6 but less influence on P020. In contrast, the E484A/K caused more loss on the activity of 7 P020 than that on P018/P019 ( Figure 3B and 3C). 8 We further assessed the 3 HCPs against 24 DM mutants, which carried combined 9 mutations with dominant effects in changing cross-species tropism or causing 10 neutralization resistance. The N439K/G446V, K444R/V483A, G446V/N440K, 11 G446V/V483A caused a near-to-over 5× NT decrease on the P018 and P019, whereas 12 only slightly decreased the activity of P020. On the contrary, the E484K/K417N weakened 13 the NT of P020 by about 4× but caused minor impairment for P018 and P019. Against the 14 N501Y/E484K, the P019 showed a delicate NT decrease than the P018 and P020. The 15 most consistent outcome fell on the G446V/E484A, which decreased the NT by 2.5-5× for 16 all 3 HCPs ( Figure 3C ). These data suggest that aa439-448 and aa484 are two essential 17 antigenic regions, where the neutralization activities of HCP antibodies are markedly 18 affected by mutations surrounding these sites. 19 Cross-neutralization profiles of the 3 HCPs against 11 VOC/VOI variants were also 20 characterized ( Figures 3D and S7B ). Remarkably, in neutralizing the Omicron, P018 and 21 P019 completely lost their activities (ID50<20), whereas P020 showed a detectable but 22 quite low titer (ID50=26). The Omicron variant caused dramatical NT attenuation for nearly 23 or over 100× for the 3 HCPs, which were even more marked than that induced by the 24 SARS1rbd (a chimeric variant with SARS-CoV RBD). For others, the P020 appeared to be 25 more sensitive than the other two to E484K-harbouring variants, including Beta, Gamma, 26 Eta, Iota_E484K, and B.1.620. For example, the P20 showed 11-15× NT decrease against 27 the Beta and Gamma, whereas the P018 and P019 presented approximately 3-5× NT 28 reduction against the two variants. Moreover, the L452R-harbouring Epsilon, Kappa, and 29 Delta caused a more arresting NT decrease in P020 than P018 or P019. By contrast, the Figure 3D ).To avoid potential bias resulting from the 3 HCP samples, we additionally 2 measured other samples in our COVID-19 cohort, which was composed of patients 3 recovered from COVID-19 (n=20), and individuals with past asymptomatic infections (ASI, 4 n=20) (Chang et al., 2021; Zhang et al., 2021) . The characteristics of the involved subjects 5 are summarized in Table S2 . Due to the limited sample volume, we just tested 8 of 11 6 involved VOC/VOI strains (not included the Kappa, Delta, and B.1.620). Against various 7 variants, the cross-neutralization profiles of longitudinal HCPs from the same subject were 8 overall consistent ( Figure S7C ) for either patients or ASIs. However, some discrepancies 9 were also noted in rare cases, particularly those (like A007, Figure S7C ) during the IgM-10 seroclearance period. The Omicron showed the most striking resistance among all variants, 11 which caused a 96.4× and 64.9× nAb GMT decrease in patients and ASIs ( Figure 3E ). The 12 E484K-harbouring Beta, Gamma, Eta, and Iota_E484K variants attenuated the nAb GMT 13 by 8.4-14.3×, 3.4-6.6×, 2.2-3.3×, and 2.5-2.6×, respectively. The remaining Alpha, Epsilon, 14 and Iota_S477N variants had less impact (~<2× decrease). Overall, HCPs either from 15 patients or ASI presented similar cross-neutralization profiles, and there was no significant 16 difference on rNT against most of these variants between the two groups ( Figure S8A ). 17 According to the cross-neutralizing patterns, all tested HCPs could be divided into 6 groups. 18 Of note, 21 of 40 (52.5%) were classified into group 1, including the P020. The P018 and 19 P019 were categorized into a distinct group 4. As shown in Figure S8C , against tested 20 variants, the NT changes of P018 (R 2 =0.741, p=0.003), P019 (R 2 =0.634, p=0.01), and 21 P020 (R 2 =0.906, p<0.001) significantly correlated with the nAb GMT changes of the cohort. 22 These data suggest the cross-variants neutralizing characteristics of the 3 HCPs, 23 particularly for the P018 and P020, can partially represent the overall antigenic profile of 24 HCPs from the early COVID-10 wave. 26 We further investigated the impacts of VOC/VOI variants and DM mutants with a 27 noticeable HCP neutralization resistance on nAbs elicited by recombinant subunit vaccine 28 in mice and monkeys. The immunized animals are derived from our previous studies, 29 including 4 monkeys and 6 mice vaccinated with spike protein (StriFK), 2 monkeys and 6 30 J o u r n a l P r e -p r o o f 11 / 30 mice immunized with recombinant RBD protein (Wu et al., 2021) . We first tested sera of 1 these animals collected at 2-week after 3-shot immunizations. The spike elicited higher 2 nAb titers in both animals than RBD ( Figure 4A ), suggesting the former was more 3 immunogenic than the latter. Against the Omicron and SARS1rbd variants, spike-elicited 4 antisera displayed significantly (p<0.05) higher rNT than that elicited by RBD ( Figure S9A ). 5 However, nAbs elicited by the two antigens showed comparable rNTs to other variants 6 ( Figures 4B and S9A ). For inter-animals comparison, mice showed significantly higher rNT 7 to 8 of 19 variants than monkeys (p<0.05, Figure S9A ). In both species, the cross-8 neutralizing profiles of vaccine-elicited antisera were more similar to human HCP P020 9 ( Figure 4C ) instead of P018/P019 ( Figures S9B and S9C) , and monkeys showed better 10 correlation on rNT against variants with that of P020 than mice ( Figure 4C ). In consistent 11 with findings using HCPs, the Omicron led the most striking nAb resistance, which caused 12 a 15× and 26× nAb GMT decrease in monkeys and mice ( Figure 4A ). Besides Omicron, 13 vaccine-elicited nAbs in both animals appeared more attenuated neutralization against the 14 E484A/K-harboring variants (Beta, Gamma, Iota_484K, B.1.620, and G446V/E484A) than 15 others. Notably, these sera displayed relatively higher NT to the VOC/VOI variants than 16 HCPs; therefore, we speculated the 3-shot immunization might be a possible explanation 17 for these differences. To validate this, we further tested the sera of spike-immunized 18 animals before the 3 rd -dose administration (2-week after 2-shot) against 7 variants. As the 19 results shown in Figures 4D and 4E , the 3 rd boost generated more nAb increase against 6 20 of 7 tested variants (except Delta) than against S-614G in both animals. Moreover, the 21 median rNTs of animals' antisera significantly (p<0.05) raised from 2-to 3-dose in To test whether the circulating frequencies of RBD mutations associate with their in 1 vitro phenotypic characteristics, we calculated the frequencies of RBD mutations from all 2 SARS-CoV-2 sequences in GISAID by January 1, 2022. We analyzed how the RBD 3 mutations were associated with their cumulative frequencies from two perspectives, the 4 one considering the cross-species breakout potentials and the other concerning the 5 neutralization escape of HCPs. By four different time points of July 1, 2020, January 1, 6 2021, July 1, 2021, and January 1, 2022, the multivariate regression analyses 7 demonstrated relative infectivity changes (fold-change to S-614G) caused by RBD 8 mutations in feACE2 cells were independently associated with their cumulative 9 prevalences (Table S3 ). This association was statistically significant in either viral 10 sequence derived from humans or non-human animals (Table S3 ). Moreover, the relative 11 infectivities of RBD mutants in muACE2 cells were also independently associated with their 12 cumulative prevalences when analyzing the summarized viral sequences in GISAID at time 13 points after 2021 (Table S3 ). In contrast, no significant association was noted between the 14 mutation prevalences and their influence on viral infectivity in huACE2-H1299 cells or the 15 neutralizing activities of HCPs at all time points we analyzed (Table S3) . 16 Following these findings, we developed a cross-species-infectivity (CSI) score (based 17 on the relative infectivities in feACE2 and muACE2 cells) to characterize the cross-species Aliquot viral stocks (supernatants) were stored at -80°C freezer until use.

The reference cDNA of 18 ACE2 orthologs (Table S1) 

2 For measurements of the binding capabilities between rACE2 and spike proteins 3 ( Figure 1D and Figure 5A ), ELISA plates were coated with StriFK or S-HexaPro at 200 4 ng/well. A series of 3-fold series dilutions that ranged from 10,000 to 0.056 ng/mL for each 5 rACE2 protein were prepared. For the assay, 100 μl of rACE2 dilutions were added to the 6 well and incubated for 1-hour at 37°C, followed by washing and reaction with the goat anti- Molenkamp, R., van der Spek, A., Tolsma, P., Rietveld, A., Brouwer, M., et al. (2021) .

Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. bioRxiv, 2022 bioRxiv, .2001 bioRxiv, .2025 bioRxiv, .477789. 10.1101 bioRxiv, /2022 Zhang, Y., Wang, S., Wu, Y., Hou, W., Yuan, L., Shen, C., Wang, J., Ye, J., Zheng, Q., Ma, J., N317D  F318L  F318S  F318C  V320G  Q321L  T323S  T323I  S325F  I326V  P330S  P337S  P337R  G339D  E340K  V341I  A344S  R346K  A348S  A352S  N354D  N354S  N354K  R357K  C361F  D364Y  V367F  L368P  N370K  N370S  S373L  T376I  V382E  V382L  P384S  P384I  T385A  L390P  V395I  R403K  R408I  A411S  G413R  G413E  Q414K  Q414R  K417N  D427Y  A435S  N439K  N440K  L441I  K444R  K444N  G446V  G447V  N448H  N448Y  N448D  N450K  L452R  Y453F  L455F  F456L  R457T  4   5   6   7   R457S  K458Q  K458N  S459F  K462N  P463S  E465G  D467V  I468T  I468V  T470N  E471K  E471D  E471Q  Y473F  Q474K  A475V  G476S  S477G  S477N  S477I  T478K  T478R  T478I  P479S  N481D  V483A  V483F  E484K  E484Q  E484A  E484D  F490L  F490S  Q493L  S494L  S494P  Q498P  N501Y  G502D  V503F  V503I  Y505C  Q506R  Y508H  R509K  S514F  L518I  H519P  H519Q  H519Y  A520S  A520V  P521S  P521R  A522S  A522V  K529M  K529E  N532K  V534I  G545S  T547I  T549A S-614G 4 5 6 7 Infectivity (log 10 GFU/0.5μg p24) Infectivity (log 10 GFU/0.5μg p24) 3   F318L  V320G  Q321L  T323S  T323I  S325F  I326V  P330S  P337S  P337R  G339D  E340K  V341I  A344S  R346K  A348S  A352S  N354D  N354S  N354K  R357K  V367F  N370K  N370S  S373L  V382L  P384S  P384I  T385A  V395I  R403K  R408I  A411S  G413R  G413E  Q414K  Q414R  K417N  D427Y  A435S  N439K  N440K  L441I  K444R  K444N  G446V  G447V  N448H  N448Y  N448D  N450K  Y453F  L455F  F456L  K458Q  K458N  S459F  K462N  P463S  E465G  I468T  I468V  T470N  E471K  E471D  E471Q  Y473F  Q474K  A475V  G476S  S477G  S477N  S477I  T478K  T478R  T478I  P479S  N481D  V483A  V483F  E484K  E484Q  E484A  E484D  F490L  F490S  Q493L  S494L  S494P  N501Y  V503F  V503I  Y508H  S514F  L518I  H519P  H519Q  H519Y  A520S  A520V  P521S  P521R  A522S  A522V  K529M  K529E  N532K  V534I  G545S  T547I  T549A  S-614D  S-614G  L452R   F318L   V320G  G413E  K417N   N439K   G447V N448Y

Horseshoe bat ACE2-H1299 cells Relative neutralizing titer (rNT)

Relative neutralizing titer (rNT) Relative neutralizing titer (rNT) Relative neutralization potency (rNP) of rhuACE2 Relative neutralization potency (rNP) of rhuACE2 Relative neutralization potency (rNP) of rhuACE2 A mAb source: hu hu hu mu hu mu mu hu mu epitope class: NTD 1 1 2 2 2 3 3 4 V395I  R403K  R408I  A411S  G413R  Q414K  K417N  D427Y  A435S  N439K  N440K  L441I  K444R  K444N  G446V  N448H  N450K  L452R  Y453F  L455F  F456L  K458Q  S459F  K462N  P463S  E465G  I468T  T470N  E471K  Y473F  Q474K  A475V  G476S  S477N  S477I  T478R  P479S  N481D  V483A  E484K  E484A  F490S  Q493L  S494L  N501Y  V503F  V503I  Y508H S-614G ** *** *** *** * *** ** * * * * * * ** ** ** *** ** ** *** ** * ** * ** 

a It is the first sampling time after illness onset. b Serological status of RBD-IgM/IgG for the

The NT of each HCP sample against the S-614G is regarded as the reference. d Indicating the fold changes of NT to a variant in comparison with that to S-614G control. The data of NT level is expressed as median±SD. The fold-change of NT

** *

characteristics of 153 SARS-CoV-2 RBD mutants and 11 globally circulating VOC/VOI variants. They reveal an association between enhanced cross-species infection potential and the current cumulative prevalence of mutations, which can inform surveillance and forecasting of SARS-CoV-2 spike mutations.

• Infection in cells with ferret or mouse ACE2 correlates with prevalence of RBD mutants.• Mutations near aa 439-448 and 484 are more likely to cause neutralization resistance.• Many spike variants of VOC/VOI strains show increased cross-species infection potential J o u r n a l P r e -p r o o f